Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). Forero-Torres, A., Moskowitz, C., Advani, R. H., Shah, B. D., Kostic, A., Albertson, T. M., Sandalic, L., Zhao, B., Fanale, M. A. AMER SOC CLINICAL ONCOLOGY. 2014
View details for DOI 10.1200/jco.2014.32.15_suppl.8505
View details for Web of Science ID 000358613204186